Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation

Bone Marrow Transplant. 2004 May;33(10):1071-2. doi: 10.1038/sj.bmt.1704468.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Immunohistochemistry
  • Liver Transplantation / adverse effects*
  • Lymphoma / etiology*
  • Lymphoma / therapy*
  • Prognosis
  • Remission Induction
  • Rituximab
  • Stem Cell Transplantation / methods*
  • Time Factors
  • Transplantation Conditioning
  • Transplantation, Autologous / methods*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • Cyclosporine